Preclinical safety studies of medicines in the Eurasian economic union

This article analyzes the regulatory, scientific, and methodological documents of the Eurasian Economic Union (EAEU) and the Russian Federation devoted to conducting preclinical studies on the safety of medicines. Areas for which it is advisable to develop special EAEU guidelines for conducting preclinical safety studies have been identified. Based on an analysis of the international regulatory and methodological framework, elements of foreign experience in preclinical assessment of the safety of medicines for transfer to the practice of the Union are proposed.

1. Reshenie Soveta EEK ot 03.11.2016 N 78 «O Pravilakh registratsii i ekspertizy lekarstvennykh sredstv dlya meditsinskogo primeneniya». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207379/?ysclid=m7permjhzg600081579. Ссылка активна на 16.08.2023.

2. Federal'nyi zakon ot 12.04.2010 N 61-F3. «Ob obrashchenii lekarstvennykh sredstv». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_99350/?ysclid=m7petqdq2n494366829. Ссылка активна на 16.08.2023.

3. Prikaz Ministerstva zdravookhraneniya RF ot 24 avgusta 2017 g. N 558n «Ob utverzhdenii Pravil provedeniya ekspertizy lekarstvennykh sredstv dlya meditsinskogo primeneniya i osobennosti ekspertizy» otdel'nykh vidov lekarstvennykh preparatov dlya meditsinskogo primeneniya (referentnykh lekarstvennykh preparatov, vosproizvedennykh lekarstvennykh preparatov, biologicheskikh lekarstvennykh preparatov, bioanalogovykh (biopodobnykh) lekarstvennykh preparatov (bioanalogov), gomeopaticheskikh lekarstvennykh preparatov, lekarstvennykh rastitel'nykh preparatov, kombinatsii lekarstvennykh preparatov), form zaklyuchenii komissii ekspertov». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_285813/2ff7a8c72de3994f30496a0ccbb1ddafdaddf518/?ysclid=m7peukydwr503100487. Ссылка активна на 16.08.2023.

4. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 N 81 «Ob utverzhdenii Pravil nadlezhashchei laboratornoi praktiki Evraziiskogo ekonomicheskogo soyuza v sfere obrashcheniya lekarstvennykh sredstv». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207468/858be1253d34b776a78f795ba872443d0d58a4c8/?ysclid=m7pevg4ag4218474202. Ссылка активна на 16.08.2023.

5. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 N 79 «Ob utverzhdenii Pravil nadlezhashchei klinicheskoi praktiki Evraziiskogo ekonomicheskogo soyuza». In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207651/?ysclid=m7pew9tfvp782539343. Ссылка активна на 16.08.2023.

6. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 N 89 «Ob utverzhdenii Pravil provedeniya issledovanii biologicheskikh lekarstvennykh sredstv Evraziiskogo ekonomicheskogo soyuza». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207925/f8a9c8bf64d706d09eb016a900a33759fc93eaa9/?ysclid=m7peycebof124791063. Ссылка активна на 16.08.2023.

7. «Dogovor o Evraziiskom ekonomicheskom soyuze» (Podpisan v g. Astane 29.05.2014) (red. ot 25.05.2023) (s izm. i dop., vstup. v silu s 24.06.2024). (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_163855/?ysclid=m7pfaytdf750058162. Ссылка активна на 16.08.2023.

8. «Dogovor o Evraziiskom ekonomicheskom soyuze» (Podpisan v g. Astane 29.05.2014) (red. ot 25.05.2023) (s izm. i dop., vstup. v silu s 24.06.2024), Prilozhenie №1. (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_163855/8e3543f8dc9861d6acfa6a0c6678b972da1d07d0. Ссылка активна на 16.08.2023.

9. Reshenie Kollegii Evraziiskoi ekonomicheskoi komissii ot 26.11.2019 N 202 (red. ot 11.10.2022) «Ob utverzhdenii Rukovodstva po doklinicheskim issledovaniyam bezopasnosti v tselyakh provedeniya klinicheskikh issledovanii i registratsii lekarstvennykh preparatov». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_339011/?ysclid=m7pfibzhv1386279121. Ссылка активна на 16.08.2023.

10. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2) - current step 4 version dated 11 june 2009. Available at: https://database.ich.org/sites/default/files/M3_R2 Guideline.pdf. Accessed August 16, 2023.

11. Guidelines for conducting preclinical studies of medicines. Part one. Moscow: Grif i K, 2012. (In Russ.).

12. Rekomendatsiya Kollegii Evraziiskoi ekonomicheskoi komissii ot 27.10.2020 N 18 "O Rukovodstve po issledovaniyu farmakologicheskoi bezopasnosti lekarstvennykh preparatov dlya meditsinskogo primeneniya". (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_366430/?ysclid=m7pfory0by303387178. Ссылка активна на 16.08.2023.

13. ICH S7A Guideline: «Safety pharmacology studies for human pharmaceuticals». 2000. Available at: https://database.ich.org/sites/default/files/S7A_Guideline.pdf. Accessed August 16, 2023.

14. ICH S7B «The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals». 2005. Available at: https://database.ich.org/sites/default/files/S7B_Guideline.pdf. Accessed August 16, 2023.

15. M. Hashimoto «Guideline on safety pharmacology studies for human pharmaceuticals (S7A)» ICH Training Library: S7A Step 4 Presentation, developed in November 2000. Available at: https://database.ich.org/sites/default/files/S7A_Step4_Presentation.pdf. Accessed August 16, 2023.

16. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 N 78 (red. ot 29.05.2024) «O Pravilakh registratsii i ekspertizy lekarstvennykh sredstv dlya meditsinskogo primeneniya». Prilozhenie N 1 «Trebovaniya k dokumentam registratsionnogo dos'e (v formate obshchego tekhnicheskogo dokumenta)». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207379/83f4280af5e62662114c8830bb17a7a6f95549c1. Ссылка активна на 16.08.2023.

17. Guidance for industry «Single dose acute toxicity testing for pharmaceuticals» Center for Drug Evaluation and Research (CDER) August 1996. Available at: https://www.fda.gov/media/72288/download. Accessed August 16, 2023.

18. EMA Scientific guideline: Questions and answers on the withdrawal of the 'note for guidance on single dose toxicity. 19.07.2010. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-withdrawal-note-guidance-single-dose-toxicity_en.pdf. Accessed August 16, 2023.

19. EMA CPMP/SWP/1042/99 Rev 1: «Guideline on repeat dose toxicity», 2010. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-repeated-dose-toxicity-revision-1_en.pdf. Accessed August 16, 2023.

20. Questions and answers on the withdrawal of the 'Note for guidance on single dose toxicity' Committee for Medicinal Products for Human Use (CHMP), 24 June 2010 EMA/CHMP/SWP/81714/2010. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-withdrawal-note-guidance-single-dose-toxicity_en.pdf. Accessed August 16, 2023.

21. Rekomendatsiya Kollegii Evraziiskoi ekonomicheskoi komissii ot 21.05.2020 N 10 «O Rukovodstve po provedeniyu doklinicheskikh issledovanii toksichnosti pri povtornom (mnogokratnom) vvedenii deistvuyushchikh veshchestv lekarstvennykh preparatov dlya meditsinskogo primeneniya». In Russ). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_353508/?ysclid=m7pghsmppe48582519. Accessed August 16, 2023.

22. ICH S3A «Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies, 1994. Available at: https://database. ich.org/sites/default/files/S3A_Guideline.pdf. Accessed August 16, 2023.

23. Rekomendatsiya Kollegii Evraziiskoi ekonomicheskoi komissii ot 22.12.2020 N 33 «O Rukovodstve po izucheniyu toksikokinetiki i otsenke sistemnogo vozdeistviya v toksikologicheskikh issledovaniyakh lekarstvennykh preparatov». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_372519/?ysclid=m7pglb95ej999344108. Ссылка активна на 16.08.2023.

24. Reshenie Soveta Evraziiskoi ekonomicheskoi komissii ot 03.11.2016 N 78 (red. ot 29.05.2024) «O Pravilakh registratsii i ekspertizy lekarstvennykh sredstv dlya meditsinskogo primeneniya». Prilozhenie N 6 «Forma ekspertnogo otcheta po otsenke rezul'tatov doklinicheskikh (neklinicheskikh) issledovanii». In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_207379/5655f7dfa255dddb5767ab4ed70fe0a9402637a1/. Ссылка активна на 16.08.2023.

25. «Guideline on non-clinical local tolerance testing of medicinal products». EMA/CHMP/SWP/2145/2000, 22 October 2015. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf. Accessed August 16, 2023.

26. Final Concept Paper S2(R1): Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use (Revision of the ICH S2 Guidelines: “Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals” (S2A) and “Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals” (S2B) 20 September 2006. Available at: https://database.ich.org/sites/default/files/S2_R1__Concept_Paper.pdf. Accessed August 16, 2023.

27. ICH S2(R1) «Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use», 2011. Available at: https://database.ich.org/sites/default/files/S2%28R1%29%20Guideline.pdf. Accessed August 16, 2023.

28. GOST R 57130-2016. Natsional'nyi standart Rossiiskoi Federatsii. «Lekarstvennye sredstva dlya meditsinskogo primeneniya. Issledovanie genotoksichnosti i interpretatsiya poluchennykh dannykh» (utv. i vveden v deistvie Prikazom Rosstandarta ot 10.10.2016 N 1345-st). (In Russ.). Доступно по: https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=OTN&n=23065&ysclid=m7pimndgb9331705566#FSxR9eUmiNEjHlx71. Ссылка активна на 16.08.2023.

29. Rekomendatsiya Kollegii Evraziiskoi ekonomicheskoi komissii ot 06.08.2019 № 23 «O Rukovodstve po otsenke i kontrolyu DNK-reaktivnykh (mutagennykh) primesei v lekarstvennykh sredstvakh i ustanovleniyu granits potentsial'nogo kantserogennogo riska». (In Russ.). Доступно по: https://www.consultant.ru/document/cons_doc_LAW_331479/?ysclid=m7pj2mdxky93800378. Ссылка активна на 16.08.2023.

30. OECD (2022), Test No. 470: Mammalian Erythrocyte Pig-a Gene Mutation Assay, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris. doi: 10.1787/4faea90e-en.

31. Durnev AD, Zhanataev AK. Relevant aspects of drug genetic toxicology. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. Regulyatornye issledovaniya i ekspertiza lekarstvennykh sredstv = Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(1):90-109. (In Russ.). doi: 10.30895/1991-2919-2022-12-1-90-109.

32. ICH S1A Guideline: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals; 1995. Available at: https://database.ich.org/sites/default/files/S1A%20Guideline.pdf. Accessed August 16, 2023.

33. «GOST R 57146-2016. Natsional'nyi standart Rossiiskoi Federatsii. Lekarstvennye sredstva dlya meditsinskogo primeneniya. Izuchenie kantserogennosti lekarstvennykh sredstv i vspomogatel'nykh veshchestv» (utv. i vveden v deistvie Prikazom Rosstandarta ot 11.10.2016 N 1369-st). (In Russ.). doi: 10.30895/1991-2919-2022-12-1-90-109.

34. ICH S1C(R2) Guideline:«Dose selection for carcinogenicity studies of pharmaceuticals», Revised on 11 March 2008. Available at: https://database.ich.org/sites/default/files/S1C%28R2%29%20Guideline.pdf. Accessed August 16, 2023.

35. ICH S1B(R1) Guideline: «Testing for carcinogenicity of pharmaceuticals », 2022. Available at: https://database.ich.org/sites/default/files/S1B-R1_FinalGuideline_2022_0719.pdf. Accessed August 16, 2023.

36. M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions & Answers (R2), 2012. Available at: https://database.ich.org/sites/default/files/M3_R2_Q%26As_R2_Q%26As_0.pdf. Accessed August 16, 2023.

37. ICH S5(R2) Guideline: Detection of reproductive and developmental toxicity for human pharmaceuticals S5(R3), 2020. Final version Adopted on 18 February 2020. Available at: https://database.ich.org/sites/default/files/S5-R3_Step4_Guideline_2020_0218_1.pdf. Accessed August 16, 2023.

38. ICH S8 Guideline: «Immunotoxicity studies for human pharmaceuticals», 2005. Available at: https://database.ich.org/sites/default/files/S8_Guideline_0.pdf. Accessed August 16, 2023.

39. EMA/CHMP/SWP/2145/2000 Rev. 1, Corr. 1: «Guideline on non-clinical local tolerance testing of medicinal products». 22 October 2015. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-local-tolerance-testing-medicinal-products_en.pdf. Accessed August 16, 2023.

40. «GOST 32372-2013. Mezhgosudarstvennyi standart. Metody ispytaniya po vozdeistviyu khimicheskoi produktsii na organizm cheloveka. In vitro 3T3 NRU test na fototoksichnost'» (vveden v deistvie Prikazom Rosstandarta ot 22.11.2013 № 773-st). (In Russ.). Доступно по: https://www.consultant.ru/. Ссылка активна на 16.08.2023.

41. ICH S10 Guideline: «Photosafety evaluation of pharmaceuticals», 2013. Available at: https://database.ich.org/sites/default/files/S10_Guideline.pdf. Accessed August 16, 2023.

42. EMEA/CHMP/SWP/94227/2004: Guideline on the non-clinical investigation of the dependence potential of medicinal products. Adoption by CHMP march 2006. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-investigation-dependence-potential-medicinal-products_en.pdf. Accessed August 16, 2023.